Key Takeaways TMO reported Q4 adjusted EPS of $6.57, up 7.7% year over year, while revenues rose 7.1% to $12.22B. TMO saw strength in Life Sciences and Laboratory Products offsetting slower growth in Analytical Instruments. TMO posted margin contraction as costs rose, even as cash and short-term investments jumped to $10.11B. Thermo Fisher Scientific Inc.'s (TMO) fourth-quarter 2025 adjusted earnings per share (EPS) of $6.57 beat the Zacks Consensus Estimate by 2.1%. The figure increased 7.7% year over year ...

Thermo Fisher Scientific (NYSE:TMO) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsCasey Woodring - VP of Life Science Tools and Diagnostics Equity ResearchDan Arias - Managing Director of Life Science and DiagnosticsMarc Casper - Chairman, President and CEOMichael Ryskin - Managing Director in Healthcare Equity ResearchRafael Tejada - VP of Investor RelationsStephen Williamson - SVP and CFOConference Call ParticipantsDan Brennan - Life Science and Diagnostic Tools Research AnalystJa ...